nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—kidney cancer—testicular cancer	0.355	1	CtDrD
Pazopanib—STK10—testicular cancer	0.183	0.463	CbGaD
Pazopanib—FGFR3—testicular cancer	0.146	0.37	CbGaD
Pazopanib—KIT—testicular cancer	0.0655	0.166	CbGaD
Pazopanib—UGT1A1—Etoposide—testicular cancer	0.0126	0.122	CbGbCtD
Pazopanib—ABCG2—Dactinomycin—testicular cancer	0.0123	0.119	CbGbCtD
Pazopanib—ABCG2—Carboplatin—testicular cancer	0.00826	0.0797	CbGbCtD
Pazopanib—CYP2C8—Ifosfamide—testicular cancer	0.00773	0.0746	CbGbCtD
Pazopanib—ABCG2—Cisplatin—testicular cancer	0.00706	0.0681	CbGbCtD
Pazopanib—ABCG2—Etoposide—testicular cancer	0.00693	0.0669	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—testicular cancer	0.00577	0.0556	CbGbCtD
Pazopanib—ABCG2—Doxorubicin—testicular cancer	0.00473	0.0456	CbGbCtD
Pazopanib—ABCG2—Methotrexate—testicular cancer	0.00458	0.0442	CbGbCtD
Pazopanib—ABCB1—Dactinomycin—testicular cancer	0.00443	0.0427	CbGbCtD
Pazopanib—CYP2C8—Etoposide—testicular cancer	0.00369	0.0356	CbGbCtD
Pazopanib—CYP3A4—Ifosfamide—testicular cancer	0.00313	0.0302	CbGbCtD
Pazopanib—CYP1A2—Etoposide—testicular cancer	0.00286	0.0276	CbGbCtD
Pazopanib—ABCB1—Vinblastine—testicular cancer	0.00277	0.0268	CbGbCtD
Pazopanib—CYP2D6—Vinblastine—testicular cancer	0.00261	0.0252	CbGbCtD
Pazopanib—ABCB1—Cisplatin—testicular cancer	0.00254	0.0246	CbGbCtD
Pazopanib—ABCB1—Etoposide—testicular cancer	0.0025	0.0241	CbGbCtD
Pazopanib—KIT—seminiferous tubule of testis—testicular cancer	0.00247	0.0609	CbGeAlD
Pazopanib—ABCB1—Doxorubicin—testicular cancer	0.00171	0.0165	CbGbCtD
Pazopanib—CYP3A4—Vinblastine—testicular cancer	0.00166	0.016	CbGbCtD
Pazopanib—ABCB1—Methotrexate—testicular cancer	0.00165	0.0159	CbGbCtD
Pazopanib—CYP2D6—Doxorubicin—testicular cancer	0.00161	0.0155	CbGbCtD
Pazopanib—CYP3A4—Etoposide—testicular cancer	0.0015	0.0145	CbGbCtD
Pazopanib—CYP3A4—Doxorubicin—testicular cancer	0.00102	0.00986	CbGbCtD
Pazopanib—SH2B3—seminal vesicle—testicular cancer	0.00076	0.0188	CbGeAlD
Pazopanib—FGFR3—embryo—testicular cancer	0.000677	0.0167	CbGeAlD
Pazopanib—RIOK2—seminal vesicle—testicular cancer	0.000636	0.0157	CbGeAlD
Pazopanib—MAP3K9—female gonad—testicular cancer	0.000632	0.0156	CbGeAlD
Pazopanib—TAOK1—gonad—testicular cancer	0.000583	0.0144	CbGeAlD
Pazopanib—STK36—seminal vesicle—testicular cancer	0.000572	0.0141	CbGeAlD
Pazopanib—PI4KB—seminal vesicle—testicular cancer	0.000563	0.0139	CbGeAlD
Pazopanib—MAP3K9—testis—testicular cancer	0.00056	0.0138	CbGeAlD
Pazopanib—AURKC—gonad—testicular cancer	0.000541	0.0134	CbGeAlD
Pazopanib—FLT4—embryo—testicular cancer	0.000529	0.0131	CbGeAlD
Pazopanib—PLK4—gonad—testicular cancer	0.000495	0.0122	CbGeAlD
Pazopanib—PIP4K2C—seminal vesicle—testicular cancer	0.000494	0.0122	CbGeAlD
Pazopanib—TAOK1—female gonad—testicular cancer	0.000474	0.0117	CbGeAlD
Pazopanib—FGF1—embryo—testicular cancer	0.00047	0.0116	CbGeAlD
Pazopanib—ITK—testis—testicular cancer	0.000462	0.0114	CbGeAlD
Pazopanib—FGFR3—gonad—testicular cancer	0.00046	0.0114	CbGeAlD
Pazopanib—SH2B3—female gonad—testicular cancer	0.000446	0.011	CbGeAlD
Pazopanib—FGFR2—embryo—testicular cancer	0.000443	0.011	CbGeAlD
Pazopanib—TAOK1—testis—testicular cancer	0.000421	0.0104	CbGeAlD
Pazopanib—STK36—gonad—testicular cancer	0.000413	0.0102	CbGeAlD
Pazopanib—FLT1—embryo—testicular cancer	0.000411	0.0101	CbGeAlD
Pazopanib—PI4KB—gonad—testicular cancer	0.000407	0.01	CbGeAlD
Pazopanib—MAP3K9—lymph node—testicular cancer	0.000406	0.01	CbGeAlD
Pazopanib—LIMK2—gonad—testicular cancer	0.000399	0.00986	CbGeAlD
Pazopanib—SH2B3—testis—testicular cancer	0.000396	0.00978	CbGeAlD
Pazopanib—AURKC—testis—testicular cancer	0.00039	0.00962	CbGeAlD
Pazopanib—FLT1—seminal vesicle—testicular cancer	0.000386	0.00953	CbGeAlD
Pazopanib—PDGFRA—embryo—testicular cancer	0.000385	0.00951	CbGeAlD
Pazopanib—EPHB6—seminal vesicle—testicular cancer	0.000382	0.00942	CbGeAlD
Pazopanib—STK16—female gonad—testicular cancer	0.00038	0.00937	CbGeAlD
Pazopanib—PLK4—Teniposide—Etoposide—testicular cancer	0.000376	0.332	CbGdCrCtD
Pazopanib—RIOK2—female gonad—testicular cancer	0.000374	0.00923	CbGeAlD
Pazopanib—BMPR1B—female gonad—testicular cancer	0.00037	0.00913	CbGeAlD
Pazopanib—TAOK3—seminal vesicle—testicular cancer	0.000364	0.00899	CbGeAlD
Pazopanib—PIP4K2C—gonad—testicular cancer	0.000357	0.00881	CbGeAlD
Pazopanib—PLK4—testis—testicular cancer	0.000356	0.0088	CbGeAlD
Pazopanib—KDR—embryo—testicular cancer	0.000347	0.00858	CbGeAlD
Pazopanib—CSF1R—embryo—testicular cancer	0.000339	0.00837	CbGeAlD
Pazopanib—MAP3K2—gonad—testicular cancer	0.000338	0.00835	CbGeAlD
Pazopanib—STK16—testis—testicular cancer	0.000337	0.00831	CbGeAlD
Pazopanib—STK36—female gonad—testicular cancer	0.000336	0.00829	CbGeAlD
Pazopanib—ITK—lymph node—testicular cancer	0.000335	0.00827	CbGeAlD
Pazopanib—RIOK2—testis—testicular cancer	0.000331	0.00818	CbGeAlD
Pazopanib—FGFR3—testis—testicular cancer	0.000331	0.00818	CbGeAlD
Pazopanib—PI4KB—female gonad—testicular cancer	0.000331	0.00816	CbGeAlD
Pazopanib—BMPR1B—testis—testicular cancer	0.000328	0.0081	CbGeAlD
Pazopanib—MAP3K19—testis—testicular cancer	0.000328	0.0081	CbGeAlD
Pazopanib—KDR—seminal vesicle—testicular cancer	0.000326	0.00806	CbGeAlD
Pazopanib—MAP2K5—seminal vesicle—testicular cancer	0.000326	0.00806	CbGeAlD
Pazopanib—LIMK2—female gonad—testicular cancer	0.000324	0.00801	CbGeAlD
Pazopanib—CSF1R—seminal vesicle—testicular cancer	0.000319	0.00786	CbGeAlD
Pazopanib—KIT—embryo—testicular cancer	0.000308	0.0076	CbGeAlD
Pazopanib—TAOK1—lymph node—testicular cancer	0.000305	0.00753	CbGeAlD
Pazopanib—PDGFRB—embryo—testicular cancer	0.000301	0.00743	CbGeAlD
Pazopanib—STK36—testis—testicular cancer	0.000298	0.00735	CbGeAlD
Pazopanib—PI4KB—testis—testicular cancer	0.000293	0.00724	CbGeAlD
Pazopanib—FLT4—female gonad—testicular cancer	0.000292	0.0072	CbGeAlD
Pazopanib—PIP4K2C—female gonad—testicular cancer	0.00029	0.00716	CbGeAlD
Pazopanib—KIT—seminal vesicle—testicular cancer	0.000289	0.00714	CbGeAlD
Pazopanib—LIMK2—testis—testicular cancer	0.000288	0.00711	CbGeAlD
Pazopanib—FGFR1—female gonad—testicular cancer	0.000288	0.0071	CbGeAlD
Pazopanib—SH2B3—lymph node—testicular cancer	0.000287	0.00709	CbGeAlD
Pazopanib—AURKC—lymph node—testicular cancer	0.000283	0.00698	CbGeAlD
Pazopanib—PDGFRB—seminal vesicle—testicular cancer	0.000282	0.00698	CbGeAlD
Pazopanib—FLT1—gonad—testicular cancer	0.000279	0.00689	CbGeAlD
Pazopanib—MAP3K2—female gonad—testicular cancer	0.000275	0.00679	CbGeAlD
Pazopanib—STK10—gonad—testicular cancer	0.000264	0.00652	CbGeAlD
Pazopanib—PDGFRA—gonad—testicular cancer	0.000261	0.00646	CbGeAlD
Pazopanib—FGF1—female gonad—testicular cancer	0.000259	0.0064	CbGeAlD
Pazopanib—FLT4—testis—testicular cancer	0.000259	0.00639	CbGeAlD
Pazopanib—PLK4—lymph node—testicular cancer	0.000258	0.00638	CbGeAlD
Pazopanib—LCK—female gonad—testicular cancer	0.000257	0.00636	CbGeAlD
Pazopanib—PIP4K2C—testis—testicular cancer	0.000257	0.00635	CbGeAlD
Pazopanib—FGFR1—testis—testicular cancer	0.000255	0.0063	CbGeAlD
Pazopanib—FGFR2—female gonad—testicular cancer	0.000245	0.00604	CbGeAlD
Pazopanib—STK16—lymph node—testicular cancer	0.000244	0.00603	CbGeAlD
Pazopanib—MAP3K2—testis—testicular cancer	0.000244	0.00602	CbGeAlD
Pazopanib—RIOK2—lymph node—testicular cancer	0.00024	0.00593	CbGeAlD
Pazopanib—BMPR1B—lymph node—testicular cancer	0.000238	0.00587	CbGeAlD
Pazopanib—CSF1R—gonad—testicular cancer	0.00023	0.00568	CbGeAlD
Pazopanib—FGF1—testis—testicular cancer	0.00023	0.00567	CbGeAlD
Pazopanib—LCK—testis—testicular cancer	0.000228	0.00564	CbGeAlD
Pazopanib—FLT1—female gonad—testicular cancer	0.000227	0.0056	CbGeAlD
Pazopanib—EPHB6—female gonad—testicular cancer	0.000224	0.00553	CbGeAlD
Pazopanib—FGFR2—testis—testicular cancer	0.000217	0.00536	CbGeAlD
Pazopanib—STK36—lymph node—testicular cancer	0.000216	0.00533	CbGeAlD
Pazopanib—STK10—female gonad—testicular cancer	0.000215	0.0053	CbGeAlD
Pazopanib—TAOK3—female gonad—testicular cancer	0.000214	0.00528	CbGeAlD
Pazopanib—PI4KB—lymph node—testicular cancer	0.000212	0.00525	CbGeAlD
Pazopanib—PDGFRA—female gonad—testicular cancer	0.000212	0.00525	CbGeAlD
Pazopanib—KIT—gonad—testicular cancer	0.000209	0.00516	CbGeAlD
Pazopanib—LIMK2—lymph node—testicular cancer	0.000209	0.00515	CbGeAlD
Pazopanib—PDGFRB—gonad—testicular cancer	0.000204	0.00504	CbGeAlD
Pazopanib—FLT1—testis—testicular cancer	0.000201	0.00497	CbGeAlD
Pazopanib—EPHB6—testis—testicular cancer	0.000199	0.00491	CbGeAlD
Pazopanib—PLK4—Doxorubicin—Epirubicin—testicular cancer	0.000196	0.173	CbGdCrCtD
Pazopanib—PLK4—Idarubicin—Epirubicin—testicular cancer	0.000196	0.173	CbGdCrCtD
Pazopanib—KDR—female gonad—testicular cancer	0.000192	0.00473	CbGeAlD
Pazopanib—MAP2K5—female gonad—testicular cancer	0.000192	0.00473	CbGeAlD
Pazopanib—STK10—testis—testicular cancer	0.00019	0.0047	CbGeAlD
Pazopanib—TAOK3—testis—testicular cancer	0.00019	0.00468	CbGeAlD
Pazopanib—PDGFRA—testis—testicular cancer	0.000188	0.00465	CbGeAlD
Pazopanib—FLT4—lymph node—testicular cancer	0.000187	0.00463	CbGeAlD
Pazopanib—CSF1R—female gonad—testicular cancer	0.000187	0.00462	CbGeAlD
Pazopanib—PIP4K2C—lymph node—testicular cancer	0.000186	0.0046	CbGeAlD
Pazopanib—FGFR1—lymph node—testicular cancer	0.000185	0.00457	CbGeAlD
Pazopanib—PLK4—Idarubicin—Doxorubicin—testicular cancer	0.000182	0.16	CbGdCrCtD
Pazopanib—PLK4—Epirubicin—Doxorubicin—testicular cancer	0.000182	0.16	CbGdCrCtD
Pazopanib—MAP3K2—lymph node—testicular cancer	0.000177	0.00436	CbGeAlD
Pazopanib—MAP2K5—testis—testicular cancer	0.00017	0.0042	CbGeAlD
Pazopanib—KDR—testis—testicular cancer	0.00017	0.0042	CbGeAlD
Pazopanib—KIT—female gonad—testicular cancer	0.00017	0.00419	CbGeAlD
Pazopanib—FGF1—lymph node—testicular cancer	0.000167	0.00411	CbGeAlD
Pazopanib—CSF1R—testis—testicular cancer	0.000166	0.0041	CbGeAlD
Pazopanib—PDGFRB—female gonad—testicular cancer	0.000166	0.0041	CbGeAlD
Pazopanib—LCK—lymph node—testicular cancer	0.000165	0.00409	CbGeAlD
Pazopanib—ABCG2—seminal vesicle—testicular cancer	0.000159	0.00392	CbGeAlD
Pazopanib—KIT—testis—testicular cancer	0.000151	0.00372	CbGeAlD
Pazopanib—PDGFRB—testis—testicular cancer	0.000147	0.00363	CbGeAlD
Pazopanib—FLT1—lymph node—testicular cancer	0.000146	0.0036	CbGeAlD
Pazopanib—EPHB6—lymph node—testicular cancer	0.000144	0.00356	CbGeAlD
Pazopanib—STK10—lymph node—testicular cancer	0.000138	0.00341	CbGeAlD
Pazopanib—TAOK3—lymph node—testicular cancer	0.000137	0.00339	CbGeAlD
Pazopanib—PDGFRA—lymph node—testicular cancer	0.000137	0.00337	CbGeAlD
Pazopanib—KDR—lymph node—testicular cancer	0.000123	0.00304	CbGeAlD
Pazopanib—MAP2K5—lymph node—testicular cancer	0.000123	0.00304	CbGeAlD
Pazopanib—CSF1R—lymph node—testicular cancer	0.00012	0.00297	CbGeAlD
Pazopanib—KIT—lymph node—testicular cancer	0.000109	0.0027	CbGeAlD
Pazopanib—PDGFRB—lymph node—testicular cancer	0.000107	0.00263	CbGeAlD
Pazopanib—ABCG2—female gonad—testicular cancer	9.32e-05	0.0023	CbGeAlD
Pazopanib—CYP2C8—testis—testicular cancer	8.5e-05	0.0021	CbGeAlD
Pazopanib—ABCB1—embryo—testicular cancer	8.34e-05	0.00206	CbGeAlD
Pazopanib—ABCG2—testis—testicular cancer	8.27e-05	0.00204	CbGeAlD
Pazopanib—ABCB1—seminal vesicle—testicular cancer	7.83e-05	0.00193	CbGeAlD
Pazopanib—CYP2D6—female gonad—testicular cancer	6.39e-05	0.00158	CbGeAlD
Pazopanib—ABCG2—lymph node—testicular cancer	5.99e-05	0.00148	CbGeAlD
Pazopanib—CYP2D6—testis—testicular cancer	5.67e-05	0.0014	CbGeAlD
Pazopanib—ABCB1—gonad—testicular cancer	5.66e-05	0.0014	CbGeAlD
Pazopanib—ABCB1—female gonad—testicular cancer	4.6e-05	0.00114	CbGeAlD
Pazopanib—Photosensitivity reaction—Methotrexate—testicular cancer	4.15e-05	0.000786	CcSEcCtD
Pazopanib—Breast disorder—Doxorubicin—testicular cancer	4.12e-05	0.00078	CcSEcCtD
Pazopanib—Anorexia—Etoposide—testicular cancer	4.11e-05	0.000779	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	4.1e-05	0.000777	CcSEcCtD
Pazopanib—Decreased appetite—Cisplatin—testicular cancer	4.1e-05	0.000776	CcSEcCtD
Pazopanib—Diarrhoea—Dactinomycin—testicular cancer	4.08e-05	0.000773	CcSEcCtD
Pazopanib—ABCB1—testis—testicular cancer	4.08e-05	0.00101	CbGeAlD
Pazopanib—Nasopharyngitis—Doxorubicin—testicular cancer	4.07e-05	0.000771	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Cisplatin—testicular cancer	4.07e-05	0.00077	CcSEcCtD
Pazopanib—Vomiting—Bleomycin—testicular cancer	4.07e-05	0.00077	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—testicular cancer	4.05e-05	0.000768	CcSEcCtD
Pazopanib—Infestation—Methotrexate—testicular cancer	4.05e-05	0.000768	CcSEcCtD
Pazopanib—Rash—Bleomycin—testicular cancer	4.03e-05	0.000764	CcSEcCtD
Pazopanib—Pain—Cisplatin—testicular cancer	4.03e-05	0.000763	CcSEcCtD
Pazopanib—Dermatitis—Bleomycin—testicular cancer	4.03e-05	0.000763	CcSEcCtD
Pazopanib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	4.02e-05	0.000761	CcSEcCtD
Pazopanib—Neutropenia—Epirubicin—testicular cancer	3.98e-05	0.000754	CcSEcCtD
Pazopanib—Abdominal distension—Doxorubicin—testicular cancer	3.96e-05	0.000751	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—testicular cancer	3.95e-05	0.000748	CcSEcCtD
Pazopanib—Asthenia—Ifosfamide—testicular cancer	3.92e-05	0.000743	CcSEcCtD
Pazopanib—Photosensitivity reaction—Epirubicin—testicular cancer	3.88e-05	0.000736	CcSEcCtD
Pazopanib—Paraesthesia—Etoposide—testicular cancer	3.88e-05	0.000734	CcSEcCtD
Pazopanib—Pruritus—Ifosfamide—testicular cancer	3.87e-05	0.000732	CcSEcCtD
Pazopanib—Haematuria—Methotrexate—testicular cancer	3.87e-05	0.000732	CcSEcCtD
Pazopanib—Pancreatitis—Doxorubicin—testicular cancer	3.86e-05	0.000731	CcSEcCtD
Pazopanib—Weight decreased—Epirubicin—testicular cancer	3.85e-05	0.000729	CcSEcCtD
Pazopanib—Dyspnoea—Etoposide—testicular cancer	3.85e-05	0.000729	CcSEcCtD
Pazopanib—Somnolence—Etoposide—testicular cancer	3.84e-05	0.000727	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—testicular cancer	3.83e-05	0.000726	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—testicular cancer	3.82e-05	0.000724	CcSEcCtD
Pazopanib—Nausea—Bleomycin—testicular cancer	3.8e-05	0.000719	CcSEcCtD
Pazopanib—Infestation—Epirubicin—testicular cancer	3.79e-05	0.000718	CcSEcCtD
Pazopanib—Infestation NOS—Epirubicin—testicular cancer	3.79e-05	0.000718	CcSEcCtD
Pazopanib—Vomiting—Dactinomycin—testicular cancer	3.79e-05	0.000718	CcSEcCtD
Pazopanib—Rash—Dactinomycin—testicular cancer	3.76e-05	0.000712	CcSEcCtD
Pazopanib—Decreased appetite—Etoposide—testicular cancer	3.75e-05	0.000711	CcSEcCtD
Pazopanib—Diarrhoea—Ifosfamide—testicular cancer	3.74e-05	0.000708	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Etoposide—testicular cancer	3.73e-05	0.000706	CcSEcCtD
Pazopanib—Fatigue—Etoposide—testicular cancer	3.72e-05	0.000705	CcSEcCtD
Pazopanib—Stomatitis—Epirubicin—testicular cancer	3.7e-05	0.0007	CcSEcCtD
Pazopanib—Jaundice—Epirubicin—testicular cancer	3.7e-05	0.0007	CcSEcCtD
Pazopanib—Pain—Etoposide—testicular cancer	3.69e-05	0.000699	CcSEcCtD
Pazopanib—Neutropenia—Doxorubicin—testicular cancer	3.68e-05	0.000697	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—testicular cancer	3.66e-05	0.000693	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—testicular cancer	3.64e-05	0.000689	CcSEcCtD
Pazopanib—Haematuria—Epirubicin—testicular cancer	3.62e-05	0.000685	CcSEcCtD
Pazopanib—Dizziness—Ifosfamide—testicular cancer	3.61e-05	0.000684	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—testicular cancer	3.59e-05	0.000681	CcSEcCtD
Pazopanib—Photosensitivity reaction—Doxorubicin—testicular cancer	3.59e-05	0.000681	CcSEcCtD
Pazopanib—Hepatobiliary disease—Epirubicin—testicular cancer	3.59e-05	0.00068	CcSEcCtD
Pazopanib—Epistaxis—Epirubicin—testicular cancer	3.58e-05	0.000678	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—testicular cancer	3.57e-05	0.000676	CcSEcCtD
Pazopanib—Weight decreased—Doxorubicin—testicular cancer	3.56e-05	0.000675	CcSEcCtD
Pazopanib—Nausea—Dactinomycin—testicular cancer	3.54e-05	0.000671	CcSEcCtD
Pazopanib—Gastrointestinal pain—Etoposide—testicular cancer	3.53e-05	0.000668	CcSEcCtD
Pazopanib—Infestation NOS—Doxorubicin—testicular cancer	3.51e-05	0.000665	CcSEcCtD
Pazopanib—Infestation—Doxorubicin—testicular cancer	3.51e-05	0.000665	CcSEcCtD
Pazopanib—Vomiting—Ifosfamide—testicular cancer	3.48e-05	0.000658	CcSEcCtD
Pazopanib—Bradycardia—Epirubicin—testicular cancer	3.47e-05	0.000657	CcSEcCtD
Pazopanib—Rash—Ifosfamide—testicular cancer	3.45e-05	0.000653	CcSEcCtD
Pazopanib—Dermatitis—Ifosfamide—testicular cancer	3.44e-05	0.000652	CcSEcCtD
Pazopanib—Haemoglobin—Epirubicin—testicular cancer	3.42e-05	0.000648	CcSEcCtD
Pazopanib—Jaundice—Doxorubicin—testicular cancer	3.42e-05	0.000648	CcSEcCtD
Pazopanib—Stomatitis—Doxorubicin—testicular cancer	3.42e-05	0.000648	CcSEcCtD
Pazopanib—Abdominal pain—Etoposide—testicular cancer	3.41e-05	0.000646	CcSEcCtD
Pazopanib—Haemorrhage—Epirubicin—testicular cancer	3.41e-05	0.000645	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—testicular cancer	3.4e-05	0.000644	CcSEcCtD
Pazopanib—Hypoaesthesia—Epirubicin—testicular cancer	3.39e-05	0.000642	CcSEcCtD
Pazopanib—Asthenia—Cisplatin—testicular cancer	3.38e-05	0.00064	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—testicular cancer	3.38e-05	0.00064	CcSEcCtD
Pazopanib—Urinary tract disorder—Epirubicin—testicular cancer	3.36e-05	0.000637	CcSEcCtD
Pazopanib—Oedema peripheral—Epirubicin—testicular cancer	3.36e-05	0.000635	CcSEcCtD
Pazopanib—Haematuria—Doxorubicin—testicular cancer	3.35e-05	0.000634	CcSEcCtD
Pazopanib—Connective tissue disorder—Epirubicin—testicular cancer	3.35e-05	0.000634	CcSEcCtD
Pazopanib—Urethral disorder—Epirubicin—testicular cancer	3.34e-05	0.000632	CcSEcCtD
Pazopanib—Hepatobiliary disease—Doxorubicin—testicular cancer	3.32e-05	0.000629	CcSEcCtD
Pazopanib—Epistaxis—Doxorubicin—testicular cancer	3.31e-05	0.000627	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—testicular cancer	3.3e-05	0.000625	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—testicular cancer	3.28e-05	0.000621	CcSEcCtD
Pazopanib—Chills—Methotrexate—testicular cancer	3.27e-05	0.000618	CcSEcCtD
Pazopanib—Nausea—Ifosfamide—testicular cancer	3.25e-05	0.000615	CcSEcCtD
Pazopanib—Diarrhoea—Cisplatin—testicular cancer	3.22e-05	0.000611	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—testicular cancer	3.22e-05	0.000609	CcSEcCtD
Pazopanib—Bradycardia—Doxorubicin—testicular cancer	3.21e-05	0.000608	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—testicular cancer	3.19e-05	0.000604	CcSEcCtD
Pazopanib—Eye disorder—Epirubicin—testicular cancer	3.18e-05	0.000603	CcSEcCtD
Pazopanib—Erythema—Methotrexate—testicular cancer	3.17e-05	0.0006	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—testicular cancer	3.17e-05	0.0006	CcSEcCtD
Pazopanib—Haemoglobin—Doxorubicin—testicular cancer	3.17e-05	0.0006	CcSEcCtD
Pazopanib—Flushing—Epirubicin—testicular cancer	3.16e-05	0.000599	CcSEcCtD
Pazopanib—Cardiac disorder—Epirubicin—testicular cancer	3.16e-05	0.000599	CcSEcCtD
Pazopanib—Haemorrhage—Doxorubicin—testicular cancer	3.15e-05	0.000597	CcSEcCtD
Pazopanib—Hypoaesthesia—Doxorubicin—testicular cancer	3.14e-05	0.000594	CcSEcCtD
Pazopanib—Urinary tract disorder—Doxorubicin—testicular cancer	3.11e-05	0.000589	CcSEcCtD
Pazopanib—Oedema peripheral—Doxorubicin—testicular cancer	3.1e-05	0.000588	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—testicular cancer	3.1e-05	0.000588	CcSEcCtD
Pazopanib—Asthenia—Etoposide—testicular cancer	3.1e-05	0.000587	CcSEcCtD
Pazopanib—Connective tissue disorder—Doxorubicin—testicular cancer	3.1e-05	0.000586	CcSEcCtD
Pazopanib—Angiopathy—Epirubicin—testicular cancer	3.09e-05	0.000585	CcSEcCtD
Pazopanib—Urethral disorder—Doxorubicin—testicular cancer	3.09e-05	0.000585	CcSEcCtD
Pazopanib—Mediastinal disorder—Epirubicin—testicular cancer	3.07e-05	0.000581	CcSEcCtD
Pazopanib—Chills—Epirubicin—testicular cancer	3.06e-05	0.000579	CcSEcCtD
Pazopanib—Pruritus—Etoposide—testicular cancer	3.05e-05	0.000578	CcSEcCtD
Pazopanib—Alopecia—Epirubicin—testicular cancer	3.01e-05	0.00057	CcSEcCtD
Pazopanib—Vomiting—Cisplatin—testicular cancer	3e-05	0.000567	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—testicular cancer	2.99e-05	0.000565	CcSEcCtD
Pazopanib—Mental disorder—Epirubicin—testicular cancer	2.98e-05	0.000565	CcSEcCtD
Pazopanib—Rash—Cisplatin—testicular cancer	2.97e-05	0.000563	CcSEcCtD
Pazopanib—Dermatitis—Cisplatin—testicular cancer	2.97e-05	0.000562	CcSEcCtD
Pazopanib—Malnutrition—Epirubicin—testicular cancer	2.96e-05	0.000561	CcSEcCtD
Pazopanib—Erythema—Epirubicin—testicular cancer	2.96e-05	0.000561	CcSEcCtD
Pazopanib—ABCB1—lymph node—testicular cancer	2.96e-05	0.00073	CbGeAlD
Pazopanib—Diarrhoea—Etoposide—testicular cancer	2.95e-05	0.000559	CcSEcCtD
Pazopanib—Eye disorder—Doxorubicin—testicular cancer	2.95e-05	0.000558	CcSEcCtD
Pazopanib—Anaemia—Methotrexate—testicular cancer	2.93e-05	0.000555	CcSEcCtD
Pazopanib—Cardiac disorder—Doxorubicin—testicular cancer	2.92e-05	0.000554	CcSEcCtD
Pazopanib—Flushing—Doxorubicin—testicular cancer	2.92e-05	0.000554	CcSEcCtD
Pazopanib—Flatulence—Epirubicin—testicular cancer	2.92e-05	0.000553	CcSEcCtD
Pazopanib—Dysgeusia—Epirubicin—testicular cancer	2.9e-05	0.00055	CcSEcCtD
Pazopanib—Angiopathy—Doxorubicin—testicular cancer	2.86e-05	0.000541	CcSEcCtD
Pazopanib—Dizziness—Etoposide—testicular cancer	2.85e-05	0.000541	CcSEcCtD
Pazopanib—Muscle spasms—Epirubicin—testicular cancer	2.85e-05	0.00054	CcSEcCtD
Pazopanib—Mediastinal disorder—Doxorubicin—testicular cancer	2.84e-05	0.000538	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—testicular cancer	2.84e-05	0.000537	CcSEcCtD
Pazopanib—Chills—Doxorubicin—testicular cancer	2.83e-05	0.000535	CcSEcCtD
Pazopanib—Nausea—Cisplatin—testicular cancer	2.8e-05	0.00053	CcSEcCtD
Pazopanib—Vision blurred—Epirubicin—testicular cancer	2.79e-05	0.000529	CcSEcCtD
Pazopanib—Alopecia—Doxorubicin—testicular cancer	2.78e-05	0.000527	CcSEcCtD
Pazopanib—Cough—Methotrexate—testicular cancer	2.76e-05	0.000524	CcSEcCtD
Pazopanib—Mental disorder—Doxorubicin—testicular cancer	2.76e-05	0.000523	CcSEcCtD
Pazopanib—Vomiting—Etoposide—testicular cancer	2.74e-05	0.00052	CcSEcCtD
Pazopanib—Malnutrition—Doxorubicin—testicular cancer	2.74e-05	0.00052	CcSEcCtD
Pazopanib—Erythema—Doxorubicin—testicular cancer	2.74e-05	0.00052	CcSEcCtD
Pazopanib—Anaemia—Epirubicin—testicular cancer	2.74e-05	0.000519	CcSEcCtD
Pazopanib—Rash—Etoposide—testicular cancer	2.72e-05	0.000515	CcSEcCtD
Pazopanib—Dermatitis—Etoposide—testicular cancer	2.72e-05	0.000515	CcSEcCtD
Pazopanib—Headache—Etoposide—testicular cancer	2.7e-05	0.000512	CcSEcCtD
Pazopanib—Flatulence—Doxorubicin—testicular cancer	2.7e-05	0.000512	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—testicular cancer	2.7e-05	0.000511	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—testicular cancer	2.7e-05	0.000511	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—testicular cancer	2.7e-05	0.000511	CcSEcCtD
Pazopanib—Dysgeusia—Doxorubicin—testicular cancer	2.69e-05	0.000509	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	2.68e-05	0.000507	CcSEcCtD
Pazopanib—Syncope—Epirubicin—testicular cancer	2.66e-05	0.000504	CcSEcCtD
Pazopanib—Leukopenia—Epirubicin—testicular cancer	2.65e-05	0.000503	CcSEcCtD
Pazopanib—Muscle spasms—Doxorubicin—testicular cancer	2.64e-05	0.000499	CcSEcCtD
Pazopanib—Loss of consciousness—Epirubicin—testicular cancer	2.61e-05	0.000493	CcSEcCtD
Pazopanib—Cough—Epirubicin—testicular cancer	2.59e-05	0.00049	CcSEcCtD
Pazopanib—Vision blurred—Doxorubicin—testicular cancer	2.59e-05	0.00049	CcSEcCtD
Pazopanib—Infection—Methotrexate—testicular cancer	2.57e-05	0.000486	CcSEcCtD
Pazopanib—Nausea—Etoposide—testicular cancer	2.56e-05	0.000486	CcSEcCtD
Pazopanib—Hypertension—Epirubicin—testicular cancer	2.56e-05	0.000485	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—testicular cancer	2.54e-05	0.00048	CcSEcCtD
Pazopanib—Anaemia—Doxorubicin—testicular cancer	2.54e-05	0.00048	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—testicular cancer	2.53e-05	0.000479	CcSEcCtD
Pazopanib—Arthralgia—Epirubicin—testicular cancer	2.52e-05	0.000478	CcSEcCtD
Pazopanib—Chest pain—Epirubicin—testicular cancer	2.52e-05	0.000478	CcSEcCtD
Pazopanib—Myalgia—Epirubicin—testicular cancer	2.52e-05	0.000478	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—testicular cancer	2.51e-05	0.000476	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	2.51e-05	0.000475	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—testicular cancer	2.5e-05	0.000473	CcSEcCtD
Pazopanib—Dry mouth—Epirubicin—testicular cancer	2.47e-05	0.000467	CcSEcCtD
Pazopanib—Anorexia—Methotrexate—testicular cancer	2.46e-05	0.000467	CcSEcCtD
Pazopanib—Syncope—Doxorubicin—testicular cancer	2.46e-05	0.000466	CcSEcCtD
Pazopanib—Leukopenia—Doxorubicin—testicular cancer	2.46e-05	0.000465	CcSEcCtD
Pazopanib—Oedema—Epirubicin—testicular cancer	2.42e-05	0.000458	CcSEcCtD
Pazopanib—Loss of consciousness—Doxorubicin—testicular cancer	2.41e-05	0.000457	CcSEcCtD
Pazopanib—Infection—Epirubicin—testicular cancer	2.4e-05	0.000455	CcSEcCtD
Pazopanib—Cough—Doxorubicin—testicular cancer	2.39e-05	0.000453	CcSEcCtD
Pazopanib—Shock—Epirubicin—testicular cancer	2.38e-05	0.000451	CcSEcCtD
Pazopanib—Nervous system disorder—Epirubicin—testicular cancer	2.37e-05	0.000449	CcSEcCtD
Pazopanib—Thrombocytopenia—Epirubicin—testicular cancer	2.37e-05	0.000449	CcSEcCtD
Pazopanib—Hypertension—Doxorubicin—testicular cancer	2.37e-05	0.000449	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—testicular cancer	2.36e-05	0.000446	CcSEcCtD
Pazopanib—Skin disorder—Epirubicin—testicular cancer	2.35e-05	0.000445	CcSEcCtD
Pazopanib—Hyperhidrosis—Epirubicin—testicular cancer	2.34e-05	0.000443	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—testicular cancer	2.34e-05	0.000443	CcSEcCtD
Pazopanib—Myalgia—Doxorubicin—testicular cancer	2.34e-05	0.000442	CcSEcCtD
Pazopanib—Chest pain—Doxorubicin—testicular cancer	2.34e-05	0.000442	CcSEcCtD
Pazopanib—Arthralgia—Doxorubicin—testicular cancer	2.34e-05	0.000442	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—testicular cancer	2.32e-05	0.00044	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	2.32e-05	0.000439	CcSEcCtD
Pazopanib—Anorexia—Epirubicin—testicular cancer	2.31e-05	0.000437	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—testicular cancer	2.31e-05	0.000437	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—testicular cancer	2.3e-05	0.000435	CcSEcCtD
Pazopanib—Dry mouth—Doxorubicin—testicular cancer	2.28e-05	0.000433	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—testicular cancer	2.28e-05	0.000431	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—testicular cancer	2.25e-05	0.000426	CcSEcCtD
Pazopanib—Oedema—Doxorubicin—testicular cancer	2.24e-05	0.000424	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—testicular cancer	2.23e-05	0.000423	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—testicular cancer	2.23e-05	0.000422	CcSEcCtD
Pazopanib—Infection—Doxorubicin—testicular cancer	2.22e-05	0.000421	CcSEcCtD
Pazopanib—Pain—Methotrexate—testicular cancer	2.21e-05	0.000419	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Epirubicin—testicular cancer	2.2e-05	0.000417	CcSEcCtD
Pazopanib—Shock—Doxorubicin—testicular cancer	2.2e-05	0.000417	CcSEcCtD
Pazopanib—Nervous system disorder—Doxorubicin—testicular cancer	2.2e-05	0.000416	CcSEcCtD
Pazopanib—Thrombocytopenia—Doxorubicin—testicular cancer	2.19e-05	0.000415	CcSEcCtD
Pazopanib—Insomnia—Epirubicin—testicular cancer	2.19e-05	0.000414	CcSEcCtD
Pazopanib—Skin disorder—Doxorubicin—testicular cancer	2.17e-05	0.000412	CcSEcCtD
Pazopanib—Paraesthesia—Epirubicin—testicular cancer	2.17e-05	0.000411	CcSEcCtD
Pazopanib—Hyperhidrosis—Doxorubicin—testicular cancer	2.16e-05	0.00041	CcSEcCtD
Pazopanib—Dyspnoea—Epirubicin—testicular cancer	2.16e-05	0.000409	CcSEcCtD
Pazopanib—Somnolence—Epirubicin—testicular cancer	2.15e-05	0.000407	CcSEcCtD
Pazopanib—Anorexia—Doxorubicin—testicular cancer	2.13e-05	0.000404	CcSEcCtD
Pazopanib—KIT—Signaling by NGF—FGFR3—testicular cancer	2.13e-05	0.000406	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—INSL3—testicular cancer	2.13e-05	0.000405	CbGpPWpGaD
Pazopanib—Dyspepsia—Epirubicin—testicular cancer	2.13e-05	0.000403	CcSEcCtD
Pazopanib—LCK—Signaling by EGFR—FGFR3—testicular cancer	2.12e-05	0.000404	CbGpPWpGaD
Pazopanib—LCK—Downstream signal transduction—KIT—testicular cancer	2.12e-05	0.000403	CbGpPWpGaD
Pazopanib—Gastrointestinal pain—Methotrexate—testicular cancer	2.11e-05	0.0004	CcSEcCtD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.11e-05	0.000402	CbGpPWpGaD
Pazopanib—LCK—Signaling by FGFR—KIT—testicular cancer	2.11e-05	0.000401	CbGpPWpGaD
Pazopanib—LCK—Signaling by EGFR in Cancer—FGFR3—testicular cancer	2.11e-05	0.0004	CbGpPWpGaD
Pazopanib—Decreased appetite—Epirubicin—testicular cancer	2.1e-05	0.000398	CcSEcCtD
Pazopanib—LCK—Signaling by ERBB2—KIT—testicular cancer	2.1e-05	0.0004	CbGpPWpGaD
Pazopanib—LCK—Signaling by PDGF—FGFR3—testicular cancer	2.1e-05	0.000398	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—INSL3—testicular cancer	2.09e-05	0.000398	CbGpPWpGaD
Pazopanib—LCK—DAP12 signaling—KIT—testicular cancer	2.09e-05	0.000398	CbGpPWpGaD
Pazopanib—Gastrointestinal disorder—Epirubicin—testicular cancer	2.09e-05	0.000396	CcSEcCtD
Pazopanib—Fatigue—Epirubicin—testicular cancer	2.09e-05	0.000395	CcSEcCtD
Pazopanib—Pain—Epirubicin—testicular cancer	2.07e-05	0.000392	CcSEcCtD
Pazopanib—LCK—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	2.06e-05	0.000392	CbGpPWpGaD
Pazopanib—Abdominal pain—Methotrexate—testicular cancer	2.04e-05	0.000387	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	2.04e-05	0.000386	CcSEcCtD
Pazopanib—KDR—Axon guidance—MMP2—testicular cancer	2.03e-05	0.000385	CbGpPWpGaD
Pazopanib—Insomnia—Doxorubicin—testicular cancer	2.02e-05	0.000383	CcSEcCtD
Pazopanib—FGFR1—Signaling by NGF—FGFR3—testicular cancer	2.02e-05	0.000385	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling by NGF—FGFR3—testicular cancer	2.02e-05	0.000384	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—KITLG—testicular cancer	2.01e-05	0.000383	CbGpPWpGaD
Pazopanib—Paraesthesia—Doxorubicin—testicular cancer	2.01e-05	0.000381	CcSEcCtD
Pazopanib—Dyspnoea—Doxorubicin—testicular cancer	2e-05	0.000378	CcSEcCtD
Pazopanib—FGFR2—Signaling by NGF—KIT—testicular cancer	1.99e-05	0.000379	CbGpPWpGaD
Pazopanib—Somnolence—Doxorubicin—testicular cancer	1.99e-05	0.000377	CcSEcCtD
Pazopanib—FGFR1—Signaling Pathways—INSL3—testicular cancer	1.99e-05	0.000378	CbGpPWpGaD
Pazopanib—LCK—B Cell Activation—FGFR3—testicular cancer	1.98e-05	0.000377	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—INSL3—testicular cancer	1.98e-05	0.000377	CbGpPWpGaD
Pazopanib—Gastrointestinal pain—Epirubicin—testicular cancer	1.98e-05	0.000375	CcSEcCtD
Pazopanib—Dyspepsia—Doxorubicin—testicular cancer	1.97e-05	0.000373	CcSEcCtD
Pazopanib—LCK—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	1.97e-05	0.000374	CbGpPWpGaD
Pazopanib—LCK—DAP12 interactions—KIT—testicular cancer	1.97e-05	0.000374	CbGpPWpGaD
Pazopanib—LCK—Signaling by FGFR in disease—KIT—testicular cancer	1.97e-05	0.000374	CbGpPWpGaD
Pazopanib—LCK—Signaling by NGF—KITLG—testicular cancer	1.96e-05	0.000373	CbGpPWpGaD
Pazopanib—LCK—Signaling by EGFR—KIT—testicular cancer	1.95e-05	0.000371	CbGpPWpGaD
Pazopanib—Decreased appetite—Doxorubicin—testicular cancer	1.95e-05	0.000369	CcSEcCtD
Pazopanib—FGF1—Immune System—BCL10—testicular cancer	1.95e-05	0.00037	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—KITLG—testicular cancer	1.93e-05	0.000368	CbGpPWpGaD
Pazopanib—LCK—Signaling by EGFR in Cancer—KIT—testicular cancer	1.93e-05	0.000367	CbGpPWpGaD
Pazopanib—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.93e-05	0.000366	CcSEcCtD
Pazopanib—Fatigue—Doxorubicin—testicular cancer	1.93e-05	0.000366	CcSEcCtD
Pazopanib—LCK—Signaling by PDGF—KIT—testicular cancer	1.92e-05	0.000366	CbGpPWpGaD
Pazopanib—Pain—Doxorubicin—testicular cancer	1.91e-05	0.000363	CcSEcCtD
Pazopanib—Abdominal pain—Epirubicin—testicular cancer	1.91e-05	0.000362	CcSEcCtD
Pazopanib—BMPR1B—Signaling Pathways—H2AFZ—testicular cancer	1.9e-05	0.000362	CbGpPWpGaD
Pazopanib—LCK—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	1.9e-05	0.000361	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—STK11—testicular cancer	1.89e-05	0.00036	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—FGFR3—testicular cancer	1.88e-05	0.000357	CbGpPWpGaD
Pazopanib—ITK—Immune System—FGFR3—testicular cancer	1.87e-05	0.000356	CbGpPWpGaD
Pazopanib—FGFR1—Signaling by NGF—KIT—testicular cancer	1.86e-05	0.000353	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—BCL10—testicular cancer	1.86e-05	0.000353	CbGpPWpGaD
Pazopanib—Asthenia—Methotrexate—testicular cancer	1.86e-05	0.000351	CcSEcCtD
Pazopanib—PDGFRA—Signaling by NGF—KIT—testicular cancer	1.85e-05	0.000352	CbGpPWpGaD
Pazopanib—CYP1A2—Biological oxidations—HPGDS—testicular cancer	1.84e-05	0.000349	CbGpPWpGaD
Pazopanib—Gastrointestinal pain—Doxorubicin—testicular cancer	1.83e-05	0.000347	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—testicular cancer	1.83e-05	0.000346	CcSEcCtD
Pazopanib—LCK—B Cell Activation—KIT—testicular cancer	1.82e-05	0.000346	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling by NGF—FGFR3—testicular cancer	1.82e-05	0.000346	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—INSL3—testicular cancer	1.79e-05	0.000339	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—BCL10—testicular cancer	1.78e-05	0.000339	CbGpPWpGaD
Pazopanib—Abdominal pain—Doxorubicin—testicular cancer	1.77e-05	0.000335	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—testicular cancer	1.77e-05	0.000335	CcSEcCtD
Pazopanib—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.76e-05	0.000335	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—KITLG—testicular cancer	1.75e-05	0.000333	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—INSL3—testicular cancer	1.75e-05	0.000332	CbGpPWpGaD
Pazopanib—LCK—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	1.74e-05	0.000331	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—H2AFZ—testicular cancer	1.74e-05	0.000331	CbGpPWpGaD
Pazopanib—Asthenia—Epirubicin—testicular cancer	1.74e-05	0.000329	CcSEcCtD
Pazopanib—FLT4—Signaling Pathways—STK11—testicular cancer	1.73e-05	0.000329	CbGpPWpGaD
Pazopanib—SH2B3—Signaling Pathways—KIT—testicular cancer	1.72e-05	0.000328	CbGpPWpGaD
Pazopanib—ITK—Immune System—KIT—testicular cancer	1.72e-05	0.000327	CbGpPWpGaD
Pazopanib—Pruritus—Epirubicin—testicular cancer	1.71e-05	0.000324	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—testicular cancer	1.71e-05	0.000324	CcSEcCtD
Pazopanib—PDGFRB—Signaling by NGF—KIT—testicular cancer	1.67e-05	0.000317	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—KITLG—testicular cancer	1.67e-05	0.000317	CbGpPWpGaD
Pazopanib—Diarrhoea—Epirubicin—testicular cancer	1.66e-05	0.000314	CcSEcCtD
Pazopanib—FGFR3—Innate Immune System—KIT—testicular cancer	1.65e-05	0.000314	CbGpPWpGaD
Pazopanib—Vomiting—Methotrexate—testicular cancer	1.64e-05	0.000311	CcSEcCtD
Pazopanib—KIT—Innate Immune System—KITLG—testicular cancer	1.64e-05	0.000311	CbGpPWpGaD
Pazopanib—Rash—Methotrexate—testicular cancer	1.63e-05	0.000309	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—testicular cancer	1.63e-05	0.000308	CcSEcCtD
Pazopanib—Headache—Methotrexate—testicular cancer	1.62e-05	0.000307	CcSEcCtD
Pazopanib—FGFR2—Immune System—BCL10—testicular cancer	1.61e-05	0.000306	CbGpPWpGaD
Pazopanib—Asthenia—Doxorubicin—testicular cancer	1.61e-05	0.000304	CcSEcCtD
Pazopanib—FLT4—Signaling Pathways—KITLG—testicular cancer	1.6e-05	0.000304	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—KITLG—testicular cancer	1.6e-05	0.000304	CbGpPWpGaD
Pazopanib—Dizziness—Epirubicin—testicular cancer	1.6e-05	0.000303	CcSEcCtD
Pazopanib—FGFR3—Adaptive Immune System—KIT—testicular cancer	1.59e-05	0.000302	CbGpPWpGaD
Pazopanib—Pruritus—Doxorubicin—testicular cancer	1.58e-05	0.0003	CcSEcCtD
Pazopanib—KIT—Immune System—BCL10—testicular cancer	1.58e-05	0.000301	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—KITLG—testicular cancer	1.57e-05	0.000299	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—KITLG—testicular cancer	1.55e-05	0.000295	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—KITLG—testicular cancer	1.55e-05	0.000295	CbGpPWpGaD
Pazopanib—Vomiting—Epirubicin—testicular cancer	1.54e-05	0.000291	CcSEcCtD
Pazopanib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	1.54e-05	0.000292	CbGpPWpGaD
Pazopanib—Nausea—Methotrexate—testicular cancer	1.54e-05	0.000291	CcSEcCtD
Pazopanib—Diarrhoea—Doxorubicin—testicular cancer	1.53e-05	0.00029	CcSEcCtD
Pazopanib—Rash—Epirubicin—testicular cancer	1.53e-05	0.000289	CcSEcCtD
Pazopanib—Dermatitis—Epirubicin—testicular cancer	1.52e-05	0.000289	CcSEcCtD
Pazopanib—Headache—Epirubicin—testicular cancer	1.52e-05	0.000287	CcSEcCtD
Pazopanib—FGFR1—Immune System—BCL10—testicular cancer	1.5e-05	0.000285	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—FGFR3—testicular cancer	1.5e-05	0.000285	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—BCL10—testicular cancer	1.5e-05	0.000285	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—KITLG—testicular cancer	1.49e-05	0.000284	CbGpPWpGaD
Pazopanib—FGFR1—Axon guidance—MMP2—testicular cancer	1.49e-05	0.000283	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—KITLG—testicular cancer	1.49e-05	0.000283	CbGpPWpGaD
Pazopanib—Dizziness—Doxorubicin—testicular cancer	1.48e-05	0.00028	CcSEcCtD
Pazopanib—LCK—Signaling by NGF—FGFR3—testicular cancer	1.46e-05	0.000278	CbGpPWpGaD
Pazopanib—KDR—Developmental Biology—MMP2—testicular cancer	1.45e-05	0.000275	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—FGFR3—testicular cancer	1.44e-05	0.000273	CbGpPWpGaD
Pazopanib—Nausea—Epirubicin—testicular cancer	1.44e-05	0.000272	CcSEcCtD
Pazopanib—LCK—Signaling Pathways—INSL3—testicular cancer	1.43e-05	0.000272	CbGpPWpGaD
Pazopanib—Vomiting—Doxorubicin—testicular cancer	1.42e-05	0.00027	CcSEcCtD
Pazopanib—FGFR3—Disease—H2AFZ—testicular cancer	1.42e-05	0.000269	CbGpPWpGaD
Pazopanib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.42e-05	0.000269	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—KITLG—testicular cancer	1.41e-05	0.000268	CbGpPWpGaD
Pazopanib—Rash—Doxorubicin—testicular cancer	1.41e-05	0.000267	CcSEcCtD
Pazopanib—Dermatitis—Doxorubicin—testicular cancer	1.41e-05	0.000267	CcSEcCtD
Pazopanib—Headache—Doxorubicin—testicular cancer	1.4e-05	0.000266	CcSEcCtD
Pazopanib—PDGFRB—Innate Immune System—KITLG—testicular cancer	1.4e-05	0.000265	CbGpPWpGaD
Pazopanib—FGF1—Innate Immune System—KIT—testicular cancer	1.37e-05	0.000261	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—KITLG—testicular cancer	1.37e-05	0.00026	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—BCL10—testicular cancer	1.35e-05	0.000256	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—KITLG—testicular cancer	1.34e-05	0.000255	CbGpPWpGaD
Pazopanib—LCK—Signaling by NGF—KIT—testicular cancer	1.34e-05	0.000255	CbGpPWpGaD
Pazopanib—Nausea—Doxorubicin—testicular cancer	1.33e-05	0.000252	CcSEcCtD
Pazopanib—LYN—Immune System—BCL10—testicular cancer	1.32e-05	0.000251	CbGpPWpGaD
Pazopanib—FGF1—Adaptive Immune System—KIT—testicular cancer	1.32e-05	0.000251	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—KITLG—testicular cancer	1.31e-05	0.00025	CbGpPWpGaD
Pazopanib—LYN—Axon guidance—MMP2—testicular cancer	1.31e-05	0.000249	CbGpPWpGaD
Pazopanib—FGFR3—Disease—KITLG—testicular cancer	1.3e-05	0.000248	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—FGFR3—testicular cancer	1.3e-05	0.000247	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—H2AFZ—testicular cancer	1.3e-05	0.000247	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—STK11—testicular cancer	1.29e-05	0.000245	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—FGFR3—testicular cancer	1.24e-05	0.000235	CbGpPWpGaD
Pazopanib—KIT—Innate Immune System—FGFR3—testicular cancer	1.22e-05	0.000231	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—KITLG—testicular cancer	1.2e-05	0.000227	CbGpPWpGaD
Pazopanib—BMPR1B—Signaling Pathways—KIT—testicular cancer	1.2e-05	0.000227	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—FGFR3—testicular cancer	1.19e-05	0.000226	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—FGFR3—testicular cancer	1.19e-05	0.000226	CbGpPWpGaD
Pazopanib—FGF1—Disease—H2AFZ—testicular cancer	1.18e-05	0.000224	CbGpPWpGaD
Pazopanib—FGF1—Immune System—KITLG—testicular cancer	1.17e-05	0.000223	CbGpPWpGaD
Pazopanib—KIT—Adaptive Immune System—FGFR3—testicular cancer	1.17e-05	0.000222	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—FGFR3—testicular cancer	1.15e-05	0.000219	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—FGFR3—testicular cancer	1.15e-05	0.000219	CbGpPWpGaD
Pazopanib—FGFR2—Innate Immune System—KIT—testicular cancer	1.14e-05	0.000216	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—KITLG—testicular cancer	1.12e-05	0.000213	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—FGFR3—testicular cancer	1.11e-05	0.000211	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—FGFR3—testicular cancer	1.11e-05	0.00021	CbGpPWpGaD
Pazopanib—FLT4—Signaling Pathways—KIT—testicular cancer	1.09e-05	0.000208	CbGpPWpGaD
Pazopanib—FGFR2—Adaptive Immune System—KIT—testicular cancer	1.09e-05	0.000208	CbGpPWpGaD
Pazopanib—FGF1—Disease—KITLG—testicular cancer	1.08e-05	0.000206	CbGpPWpGaD
Pazopanib—LCK—Immune System—BCL10—testicular cancer	1.08e-05	0.000206	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—KITLG—testicular cancer	1.08e-05	0.000205	CbGpPWpGaD
Pazopanib—FGFR1—Developmental Biology—MMP2—testicular cancer	1.06e-05	0.000202	CbGpPWpGaD
Pazopanib—FGFR1—Innate Immune System—KIT—testicular cancer	1.06e-05	0.000202	CbGpPWpGaD
Pazopanib—PDGFRA—Innate Immune System—KIT—testicular cancer	1.06e-05	0.000201	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	1.04e-05	0.000197	CbGpPWpGaD
Pazopanib—FGFR1—Adaptive Immune System—KIT—testicular cancer	1.02e-05	0.000194	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—FGFR3—testicular cancer	1.02e-05	0.000193	CbGpPWpGaD
Pazopanib—PDGFRA—Adaptive Immune System—KIT—testicular cancer	1.02e-05	0.000193	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.01e-05	0.000193	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	9.96e-06	0.000189	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—H2AFZ—testicular cancer	9.92e-06	0.000189	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—STK11—testicular cancer	9.86e-06	0.000187	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—FGFR3—testicular cancer	9.76e-06	0.000185	CbGpPWpGaD
Pazopanib—FGFR2—Disease—H2AFZ—testicular cancer	9.74e-06	0.000185	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—KITLG—testicular cancer	9.71e-06	0.000185	CbGpPWpGaD
Pazopanib—FGFR3—Immune System—KIT—testicular cancer	9.63e-06	0.000183	CbGpPWpGaD
Pazopanib—KIT—Disease—H2AFZ—testicular cancer	9.57e-06	0.000182	CbGpPWpGaD
Pazopanib—KIT—Immune System—KITLG—testicular cancer	9.54e-06	0.000181	CbGpPWpGaD
Pazopanib—PDGFRB—Innate Immune System—KIT—testicular cancer	9.53e-06	0.000181	CbGpPWpGaD
Pazopanib—LYN—Developmental Biology—MMP2—testicular cancer	9.36e-06	0.000178	CbGpPWpGaD
Pazopanib—LYN—Innate Immune System—KIT—testicular cancer	9.33e-06	0.000177	CbGpPWpGaD
Pazopanib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	9.15e-06	0.000174	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KITLG—testicular cancer	9.13e-06	0.000173	CbGpPWpGaD
Pazopanib—FGFR1—Disease—H2AFZ—testicular cancer	9.08e-06	0.000173	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—H2AFZ—testicular cancer	9.06e-06	0.000172	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KITLG—testicular cancer	9.05e-06	0.000172	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KITLG—testicular cancer	9.03e-06	0.000172	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KITLG—testicular cancer	8.96e-06	0.00017	CbGpPWpGaD
Pazopanib—LYN—Adaptive Immune System—KIT—testicular cancer	8.96e-06	0.00017	CbGpPWpGaD
Pazopanib—FGFR3—Disease—KIT—testicular cancer	8.89e-06	0.000169	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—FGFR3—testicular cancer	8.88e-06	0.000169	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	8.87e-06	0.000169	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—STK11—testicular cancer	8.82e-06	0.000168	CbGpPWpGaD
Pazopanib—KIT—Disease—KITLG—testicular cancer	8.8e-06	0.000167	CbGpPWpGaD
Pazopanib—FGF1—Immune System—FGFR3—testicular cancer	8.72e-06	0.000166	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—H2AFZ—testicular cancer	8.64e-06	0.000164	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—STK11—testicular cancer	8.59e-06	0.000163	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—HPGDS—testicular cancer	8.57e-06	0.000163	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KITLG—testicular cancer	8.36e-06	0.000159	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KITLG—testicular cancer	8.33e-06	0.000158	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—FGFR3—testicular cancer	8.33e-06	0.000158	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—H2AFZ—testicular cancer	8.25e-06	0.000157	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—STK11—testicular cancer	8.2e-06	0.000156	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—H2AFZ—testicular cancer	8.16e-06	0.000155	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	8.16e-06	0.000155	CbGpPWpGaD
Pazopanib—FLT1—Signaling Pathways—KIT—testicular cancer	8.15e-06	0.000155	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KITLG—testicular cancer	8.13e-06	0.000155	CbGpPWpGaD
Pazopanib—FGF1—Disease—FGFR3—testicular cancer	8.05e-06	0.000153	CbGpPWpGaD
Pazopanib—FGF1—Immune System—KIT—testicular cancer	8.01e-06	0.000152	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—FGFR3—testicular cancer	8e-06	0.000152	CbGpPWpGaD
Pazopanib—LYN—Immune System—KITLG—testicular cancer	7.96e-06	0.000151	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KITLG—testicular cancer	7.95e-06	0.000151	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—HPGDS—testicular cancer	7.85e-06	0.000149	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—KIT—testicular cancer	7.65e-06	0.000145	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KITLG—testicular cancer	7.59e-06	0.000144	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KITLG—testicular cancer	7.51e-06	0.000143	CbGpPWpGaD
Pazopanib—FGF1—Disease—KIT—testicular cancer	7.39e-06	0.00014	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—KIT—testicular cancer	7.34e-06	0.00014	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—HPGDS—testicular cancer	7.27e-06	0.000138	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—FGFR3—testicular cancer	7.22e-06	0.000137	CbGpPWpGaD
Pazopanib—KIT—Immune System—FGFR3—testicular cancer	7.09e-06	0.000135	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.05e-06	0.000134	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—H2AFZ—testicular cancer	6.82e-06	0.00013	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—STK11—testicular cancer	6.78e-06	0.000129	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—FGFR3—testicular cancer	6.73e-06	0.000128	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—FGFR3—testicular cancer	6.71e-06	0.000128	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—H2AFZ—testicular cancer	6.7e-06	0.000127	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—STK11—testicular cancer	6.66e-06	0.000127	CbGpPWpGaD
Pazopanib—FGFR2—Disease—FGFR3—testicular cancer	6.66e-06	0.000127	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—KIT—testicular cancer	6.63e-06	0.000126	CbGpPWpGaD
Pazopanib—LCK—Disease—H2AFZ—testicular cancer	6.55e-06	0.000124	CbGpPWpGaD
Pazopanib—KIT—Disease—FGFR3—testicular cancer	6.54e-06	0.000124	CbGpPWpGaD
Pazopanib—LCK—Immune System—KITLG—testicular cancer	6.53e-06	0.000124	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—H2AFZ—testicular cancer	6.36e-06	0.000121	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—H2AFZ—testicular cancer	6.34e-06	0.000121	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—STK11—testicular cancer	6.32e-06	0.00012	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—STK11—testicular cancer	6.31e-06	0.00012	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KITLG—testicular cancer	6.28e-06	0.000119	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—KIT—testicular cancer	6.23e-06	0.000118	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—STK11—testicular cancer	6.23e-06	0.000118	CbGpPWpGaD
Pazopanib—FGFR1—Disease—FGFR3—testicular cancer	6.21e-06	0.000118	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—FGFR3—testicular cancer	6.19e-06	0.000118	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—KIT—testicular cancer	6.18e-06	0.000117	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—KITLG—testicular cancer	6.17e-06	0.000117	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—KIT—testicular cancer	6.16e-06	0.000117	CbGpPWpGaD
Pazopanib—FGFR2—Disease—KIT—testicular cancer	6.12e-06	0.000116	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	6.06e-06	0.000115	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—FGFR3—testicular cancer	6.04e-06	0.000115	CbGpPWpGaD
Pazopanib—LCK—Disease—KITLG—testicular cancer	6.03e-06	0.000115	CbGpPWpGaD
Pazopanib—LYN—Immune System—FGFR3—testicular cancer	5.92e-06	0.000112	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—FGFR3—testicular cancer	5.91e-06	0.000112	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KITLG—testicular cancer	5.85e-06	0.000111	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KITLG—testicular cancer	5.84e-06	0.000111	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	5.72e-06	0.000109	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—STK11—testicular cancer	5.71e-06	0.000108	CbGpPWpGaD
Pazopanib—FGFR1—Disease—KIT—testicular cancer	5.7e-06	0.000108	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—KIT—testicular cancer	5.69e-06	0.000108	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—STK11—testicular cancer	5.68e-06	0.000108	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—FGFR3—testicular cancer	5.64e-06	0.000107	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—H2AFZ—testicular cancer	5.6e-06	0.000106	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—FGFR3—testicular cancer	5.58e-06	0.000106	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—KIT—testicular cancer	5.57e-06	0.000106	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—STK11—testicular cancer	5.56e-06	0.000106	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—KIT—testicular cancer	5.55e-06	0.000105	CbGpPWpGaD
Pazopanib—LYN—Immune System—KIT—testicular cancer	5.43e-06	0.000103	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—KIT—testicular cancer	5.43e-06	0.000103	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—STK11—testicular cancer	5.28e-06	0.0001	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	5.26e-06	9.99e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—KIT—testicular cancer	5.18e-06	9.84e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KITLG—testicular cancer	5.15e-06	9.78e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—KIT—testicular cancer	5.12e-06	9.74e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—FGFR3—testicular cancer	4.85e-06	9.22e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—FGFR3—testicular cancer	4.67e-06	8.87e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—H2AFZ—testicular cancer	4.59e-06	8.72e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—FGFR3—testicular cancer	4.58e-06	8.71e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—STK11—testicular cancer	4.56e-06	8.67e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—HPGDS—testicular cancer	4.51e-06	8.58e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—FGFR3—testicular cancer	4.48e-06	8.51e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—KIT—testicular cancer	4.45e-06	8.46e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—FGFR3—testicular cancer	4.35e-06	8.27e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—FGFR3—testicular cancer	4.34e-06	8.24e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—KIT—testicular cancer	4.28e-06	8.14e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KITLG—testicular cancer	4.22e-06	8.02e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—KIT—testicular cancer	4.11e-06	7.81e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—KIT—testicular cancer	3.99e-06	7.59e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—KIT—testicular cancer	3.98e-06	7.57e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—HPGDS—testicular cancer	3.93e-06	7.47e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	3.91e-06	7.43e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—FGFR3—testicular cancer	3.83e-06	7.27e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—HPGDS—testicular cancer	3.7e-06	7.04e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—KIT—testicular cancer	3.59e-06	6.82e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—KIT—testicular cancer	3.51e-06	6.68e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—STK11—testicular cancer	3.28e-06	6.23e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HPGDS—testicular cancer	3.14e-06	5.97e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—FGFR3—testicular cancer	3.14e-06	5.96e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KIT—testicular cancer	2.88e-06	5.47e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—STK11—testicular cancer	2.86e-06	5.43e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—STK11—testicular cancer	2.69e-06	5.12e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HPGDS—testicular cancer	2.42e-06	4.6e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—STK11—testicular cancer	2.28e-06	4.33e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—STK11—testicular cancer	1.76e-06	3.34e-05	CbGpPWpGaD
